Cargando…
Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy
Immune checkpoint inhibitors targeting programmed cell death protein 1, programmed death-ligand 1, and cytotoxic T-lymphocyte-associated protein 4 provide deep and durable treatment responses which have revolutionized oncology. However, despite over 40% of cancer patients being eligible to receive i...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9420297/ https://www.ncbi.nlm.nih.gov/pubmed/36031601 http://dx.doi.org/10.1186/s13045-022-01335-y |